CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective vigilantly but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. My first CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set away the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a highly promotional image in the Uptick Newswire job interview that I came away with a poor opinion of the business.

Irony of irony, the bad opinion of mine of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s payment of $3.5 million transfers ownership of this expertise as well as connected intellectual property coming from Progenics to CytoDyn, as well as roughly twenty five million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) plus the first new drug application approval ($5 million), and even royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it’s this individual therapies in addition to a “broad pipeline of indications” as it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple illness sorts, multiple publications and multiple presentations.

Can all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really beginning of the interest of mine in this company. Judging by the multiples of thousands of diverse commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this question.

CytoDyn is a classic battleground, or some could say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News